|
 |
| home > epc > autumn 2003 > make or buy? a strategic assessment of the benefits of outsourcing |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Outsourcing has many converts across the manufacturing sector. But rather than join the evangelical throng urging companies to shed assets and be born again as product designers, solutions providers, industry innovators or supply chain integrators, this article advises manufacturers to take more of an agnostic approach and not to regard outsourcing as a panacea for every ill.
On the surface, the arguments for outsourcing are compelling. Improved information technology and communication links, falling interaction costs and global access to vendors mean that manufacturers now can choose more freely than ever before how to structure their business. In one stroke, outsourcing seems to offer the chance to dump operational headaches and bottlenecks, sidestep labour conflicts and management deficiencies and secure immediate cost savings.
But, while it is undoubtedly true that outsourcing lightens a company's asset base, if manufacturers automatically assume that it is the solution they will be failing to address the core question - that of how to improve a company's performance and maximise value.
Statistics indicate that growing numbers of businesses are becoming disenchanted with outsourcing. Dun & Bradstreet report that 20 to 25 per cent of all outsourcing relationships fail within two years and 50 per cent fail within five, the costs of which are high. Possible ramifications for a company include one-time and year-on-year financial goals being missed, delays in outsourcing timelines, lowered workforce morale and productivity, dissatisfied customers, greater consumption of management resources and large switching costs should operations need to be brought back in-house.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
